Debiopharm International S.A. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Debiopharm International S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Debiopharm International S.A. - Product Pipeline Review - 2014', provides an overview of the Debiopharm International S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Debiopharm International S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Debiopharm International S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Debiopharm International S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Debiopharm International S.A.'s pipeline products

Reasons to buy

- Evaluate Debiopharm International S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Debiopharm International S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Debiopharm International S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Debiopharm International S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Debiopharm International S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Debiopharm International S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Debiopharm International S.A. Snapshot 6
Debiopharm International S.A. Overview 6
Key Information 6
Key Facts 6
Debiopharm International S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
Debiopharm International S.A. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Debiopharm International S.A. - Pipeline Products Glance 15
Debiopharm International S.A. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Debiopharm International S.A. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Debiopharm International S.A. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Debiopharm International S.A. - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Debiopharm International S.A. - Drug Profiles 21
triptorelin pamoate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
alisporivir 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Debio-1452 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AT-406 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Debio-0932 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Debio-1347 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Debio-1450 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Debio-0617B 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Debio-0719 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Debio-0929 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Debio-0930B 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Debio-1036 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Debio-0826 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Debio-1142 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Debio-1348 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Debio-1449 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Debio-1453 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Debio-1454 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit MIF for Autoimmune and Inflammatory Diseases 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Debiopharm International S.A. - Pipeline Analysis 46
Debiopharm International S.A. - Pipeline Products by Target 46
Debiopharm International S.A. - Pipeline Products by Route of Administration 48
Debiopharm International S.A. - Pipeline Products by Molecule Type 49
Debiopharm International S.A. - Pipeline Products by Mechanism of Action 50
Debiopharm International S.A. - Recent Pipeline Updates 52
Debiopharm International S.A. - Dormant Projects 58
Debiopharm International S.A. - Locations And Subsidiaries 59
Head Office 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Debiopharm International S.A., Key Information 6
Debiopharm International S.A., Key Facts 6
Debiopharm International S.A. - Pipeline by Indication, 2014 9
Debiopharm International S.A. - Pipeline by Stage of Development, 2014 11
Debiopharm International S.A. - Monotherapy Products in Pipeline, 2014 12
Debiopharm International S.A. - Partnered Products in Pipeline, 2014 13
Debiopharm International S.A. - Partnered Products/ Combination Treatment Modalities, 2014 14
Debiopharm International S.A. - Phase III, 2014 15
Debiopharm International S.A. - Phase II, 2014 16
Debiopharm International S.A. - Phase I, 2014 17
Debiopharm International S.A. - Preclinical, 2014 18
Debiopharm International S.A. - Discovery, 2014 19
Debiopharm International S.A. - Unknown, 2014 20
Debiopharm International S.A. - Pipeline by Target, 2014 47
Debiopharm International S.A. - Pipeline by Route of Administration, 2014 48
Debiopharm International S.A. - Pipeline by Molecule Type, 2014 49
Debiopharm International S.A. - Pipeline Products by Mechanism of Action, 2014 51
Debiopharm International S.A. - Recent Pipeline Updates, 2014 52
Debiopharm International S.A. - Dormant Developmental Projects,2014 58